Syndax Pharmaceuticals stock drops 3.77% amid National Cancer Survivors Day tweet, Syndax notes

Traders Union
All News
Companies
Syndax Pharmaceuticals drops 3.77% today

Highlights

SNDX continues to trade in a clear bearish trend, remaining below key moving averages across all timeframes.
Momentum and oscillators indicate persistent selling pressure, with the stock in oversold conditions and weak trend momentum.
Expected trading for the coming week is range-bound between $16.90 and $18.10, with limited upside probability and major resistance at $19.40–$19.80.

Sustained selling pressure as price holds below major moving averages

SNDX is trading at $17.34, which is below the MA-20 ($19.67), MA-50 ($21.53), and MA-200 ($19.40), confirming persistent pressure from sellers across short-, medium-, and long-term timeframes. The Ichimoku Kijun on D1 is at $19.80, now acting as immediate resistance; near-term support is found at the HMA ($17.56) and MA-100 ($21.61), while key resistance is clustered at the MA-200 ($19.40) and the Kijun ($19.80).

Oversold momentum signals deepen as weekly losses accelerate

Momentum indicators on D1 such as MACD and ADX both signal a bearish trend, with MACD showing a negative reading and ADX remaining neutral but weak. RSI (27.35 D1), Stoch RSI (0.00 D1), and CCI (–178.32 D1) all point to oversold conditions, while BBP at –0.87 signals sustained seller dominance intraday. The Awesome Oscillator further reinforces the bearish bias. SNDX has fallen $2.25 (11.49%) since last week's close at $19.59, leaving it at the very bottom of the weekly range; weekly volatility stands at a pronounced 15.80%. The current tone is a steady decline from the recent high, with today’s session also seeing a notable daily drop of 3.77%.

Downside scenario favored as bullish signals remain absent

Looking ahead, the expected price range for the coming week is $16.90 to $18.10, anchored by recent support and resistance while respecting the typical weekly volatility. The probability of a price increase is very low (less than 20%), given that neither RSI-W1, ADX-W1, MACD-W1, nor MA-50-W1 provide a Buy signal, making further downside more likely in the near term. The baseline scenario is range-bound trading between $16.90 and $18.10. A bullish breakout above $18.10 could test the $19.40–$19.80 resistance cluster, while a break below $16.90 may put pressure toward longer-term key support, though still comfortably above the 52-week low ($8.59) and well below the 52-week high ($25.59).

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that Syndax Pharmaceuticals was experiencing sustained downward momentum, with technical indicators suggesting persistent bearish sentiment. In the current environment, investors should continue to monitor for any upside catalysts while remaining cautious of continued volatility and downside risk.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.